# A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

> **NCT02028065** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 382 (actual)

## Conditions studied

- Hypersensitivity
- Anaphylaxis

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02028065
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-03
- **Primary completion:** 2014-07-01
- **Final completion:** 2014-07-01
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028065, "A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02028065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*